Is Sanofi Consumer Healthcare India a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
Sanofi Consumer Healthcare India share price around Rs 4,184. 21.9% below 52-week high of Rs 5,357. Q1 FY27 revenue Rs 236 crore, up 6.7% YoY. PAT Rs 69 crore, up 13.3%. PE 36x.
Quick Answer
Sanofi Consumer Healthcare India’s Q1 FY27 results were broadly steady, with revenue at Rs 236 crore and PAT at Rs 69 crore. The Sanofi Consumer Healthcare India share price near Rs 4,184 has not moved sharply on this print, and investors asking whether Sanofi Consumer Healthcare India is a good buy should look at the underlying margin trend rather than the headline numbers alone.
The Sanofi Consumer Healthcare India share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Sanofi Consumer Healthcare India is the consumer healthcare business demerged from Sanofi India, focused on OTC and wellness brands, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 236 crore, up 6.7% year on year, while profit after tax came in at Rs 69 crore, up 13.3% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Sanofi Consumer Healthcare India share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Sanofi Consumer Healthcare India share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Sanofi Consumer Healthcare India Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 236 crore | Rs 221 crore | 6.7% |
| Net Profit / (Loss) | Rs 69 crore | Rs 61 crore | 13.3% |
Sanofi Consumer Healthcare India Q1 FY27 Performance Analysis
Check Sanofi Consumer Healthcare India Fundamentals on Univest Screener
Revenue growth of 6.7% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the consumer healthcare and OTC wellness products sector.
Profitability moved broadly in line with revenue this quarter, with PAT at Rs 69 crore against Rs 61 crore a year earlier. There is no major surprise in either direction, and the Sanofi Consumer Healthcare India share price has traded accordingly, without a sharp re-rating either way.
Sequential quarterly data was not fully available for this comparison, so investors should track the next quarter’s results to build out the trend behind the Sanofi Consumer Healthcare India share price.
Key Business Factors in Q1 FY27
Revenue Trend
Sanofi Consumer Healthcare India’s revenue grew 6.7% year on year this quarter, taking the quarterly base to Rs 236 crore in a consumer healthcare and OTC wellness products business that remains sensitive to demand and pricing cycles that ultimately feed through to the Sanofi Consumer Healthcare India share price.
Profitability Trend
Profit before tax came in at NA for the quarter, a figure worth tracking alongside the headline PAT number for a fuller picture of the quarter.
Balance Sheet Position
Sanofi Consumer Healthcare India’s balance sheet metrics were not fully available for this quarter and should be checked against the company’s official filings before making an investment decision.
Valuation Context
Sanofi Consumer Healthcare India does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Sanofi Consumer Healthcare India share price.
Dividend Details
No interim dividend was declared alongside Sanofi Consumer Healthcare India’s Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Sanofi Consumer Healthcare India share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Sanofi Consumer Healthcare India Share Price Outlook for FY27
Sanofi Consumer Healthcare India’s FY27 outlook looks steady rather than dramatic based on this quarter’s numbers. Investors should watch for any change in margin trend or demand commentary from management in the next results for a clearer signal on where the Sanofi Consumer Healthcare India share price heads from here.
Without a major catalyst in either direction, the Sanofi Consumer Healthcare India share price is likely to keep tracking the company’s quarterly execution more than any single headline number.
Sanofi Consumer Healthcare India Stock Performance
Download the Univest iOS App or Univest Android App to track Sanofi Consumer Healthcare India’s live share price and get daily stock updates.
The Sanofi Consumer Healthcare India share price was trading around Rs 4,184 as results season played out in late August 2026, roughly 21.9% below its 52-week high of Rs 5,357 and well above its 52-week low of Rs 3,975.
The Sanofi Consumer Healthcare India share price has moved without much drama on this result, consistent with a quarter that did not materially change the investment case either way.
Key Risks
Sector and Demand Risk
As a consumer healthcare and OTC wellness products business, Sanofi Consumer Healthcare India’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Sanofi Consumer Healthcare India share price well before the next result.
Execution Risk
Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
Conclusion
Sanofi Consumer Healthcare India’s Q1 FY27 results were steady rather than exciting, with revenue at Rs 236 crore and PAT at Rs 69 crore. The Sanofi Consumer Healthcare India share price does not present a strong case either to buy aggressively or to avoid the stock based on this quarter alone, and investors should track the next result for a clearer trend.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Sanofi Consumer Healthcare India Q1 FY27 Results
What were Sanofi Consumer Healthcare India’s Q1 FY27 results?
Ans. Sanofi Consumer Healthcare India reported Q1 FY27 revenue of Rs 236 crore, up 6.7% year on year, and PAT of Rs 69 crore, up 13.3% year on year.
Is Sanofi Consumer Healthcare India a good buy after its Q1 FY27 results?
Ans. Sanofi Consumer Healthcare India’s results were largely in line with expectations this quarter, so the case to buy or avoid rests more on the broader trend than on this single print. Investors should form their own view based on their own risk appetite and time horizon.
What is the Sanofi Consumer Healthcare India share price today?
Ans. The Sanofi Consumer Healthcare India share price was trading around Rs 4,184 in late August 2026, about 21.9% below its 52-week high of Rs 5,357 and well above its 52-week low of Rs 3,975.
What is Sanofi Consumer Healthcare India’s revenue and profit for Q1 FY27?
Ans. Sanofi Consumer Healthcare India reported revenue of Rs 236 crore and a net profit of Rs 69 crore for the quarter ended June 30, 2026.
Did Sanofi Consumer Healthcare India declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Sanofi Consumer Healthcare India’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Sanofi Consumer Healthcare India’s PE ratio and is it expensive?
Ans. The Sanofi Consumer Healthcare India share price trades at a trailing PE of 36.5x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Sanofi Consumer Healthcare India investors right now?
Ans. As a consumer healthcare and OTC wellness products business, Sanofi Consumer Healthcare India’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Sanofi Consumer Healthcare India share price well before the next result. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
What is Sanofi Consumer Healthcare India’s promoter shareholding?
Ans. Promoter shareholding data for Sanofi Consumer Healthcare India was not fully available for this quarter and should be checked on the company’s official filings.